CTRI/2010/091/000483已完成3 期
ASSESSMENT OF EFFICACY, SAFETY ANDTOLERABILITY OF FIXED DOSE COMBINATION OF MOMETASONE 0.1% + FUSIDIC ACID 2% IN TREATMENT OF PATIENTS WITH CORTICOSTEROID-RESPONSIVE DERMATOSES WITH SECONDARY BACTERIAL INFECTIONS
Glenmark Pharmaceuticals Ltd.0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male & female (post-menopausal, surgically sterilized or practicing a reliable method of birth control) patients with age ranging from 12 to 65 years.
- •Clinical diagnosis of patients with infected dermatoses
- •Written informed consent by patient.
- •Patient willing to follow up.
排除标准
- •Pregnant and lactating women.
- •Serious skin disorders, dyspigmentation and extensive scarring in the affected areas.
- •Hypersensitivity to Mometasone or Fusidic acid or cream base.
- •Immuno-compromised states and patients with systemic infections.
- •Patients who have participated in a new drug study in the past 6 months.
- •Patients with severe cardiac, hepatic, renal, or cerebrovascular disease, malignancy, chronic uncontrolled systemic diseases e.g., diabetes, hypertension, asthma, collagen disorders, etc. or any other serious medical illness.
- •Any other condition that in the opinion of the investigator does not justify the patient?s participation in the study.
研究者
相似试验
已完成
3 期
A clinical study to study the effects of a cream containing a fixed -dose of Halobetasol propionate and Fusidic acid in patients with infected dermatosesCTRI/2010/091/000482Glenmark Pharmaceuticals Ltd.100
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
已完成
不适用
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-GBGM Biopharmaceuticals, Inc.150